Cadaveric renal transplantation in the cyclosporine and OKT3 eras: an update of the University of Wisconsin-Madison experience.
1. Quadruple immunosuppression yields excellent early renal allograft survival in primary renal transplant recipients when compared with non-primary renal transplant recipients. Although significant, the difference between primary and nonprimary recipients at 5 years has narrowed considerably (8%). 2. No beneficial effect of HLA or DR matching was noted in this study in primary transplant recipients. However, a trend toward improved graft survival was noted when patients with greater than or equal to 3 antigens matched or less than 3 antigens mismatched were compared to their counterparts. Further analysis of variables related to graft loss is required before statements regarding this trend can be made. 3. Significantly better results in nonprimary renal transplantation continues to be seen in DR matched recipients. Additionally, the use of OKT3 rather than ALG in DR matched recipients has resulted in a 92.3% 3-year allograft survival despite over half of these patients being highly sensitized. 4. Further follow-up of 2 high-risk groups of patients (diabetics and elderly patients) revealed significant decreases in patient survival at 5 years. This difference was not apparent in our earlier results (3-year follow-up) published in Clinical Transplants 1987. Despite this difference, we believe renal transplantation should continue to be offered to diabetic and elderly patients without other contraindications to transplantation. 5. The availability of the monoclonal antibody OKT3 during the CsA era has resulted in a trend toward improved patient and graft survival when compared with patients in the CsA pre-OKT3 era. This trend toward improved survival is also seen in the high-risk diabetic recipients.
D'Alessandro
A M
AM
University of Wisconsin-Madison, Transplant Service.
Lorentzen
D F
DF
Pirsch
J D
JD
Knechtle
S J
SJ
Reed
A
A
Hoffmann
R M
RM
Armbrust
M J
MJ
Sollinger
H W
HW
Kalayoglu
M
M
Belzer
F O
FO
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002102:Cadaver; D003524:Cyclosporins / Q000627:therapeutic use*; D006084:Graft Rejection; D006680:HLA Antigens; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology / Q000379:methods* / Q000706:statistics & numerical data; D009926:Organ Preservation; D009927:Tissue and Organ Procurement
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D006680:HLA Antigens